Media Advisory: DoseMe Bioinformatician and Dr. Marc Scheetz Co-Author Poster to Be Presented at the 26th ESCMID Annual Meeting
In this article:
Tampa, FL – April 17, 2026
DoseMe, a leading provider of model-informed precision dosing (MIPD), today announced Dr. Marc Scheetz, will present, Can therapeutic drug monitoring improve detection of vancomycin-associated acute kidney injuries?, at Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) on April 20.
ECSMID is the annual meeting of the European Society of Clinical Microbiology and Infectious Diseases, a registered non-profit organization in Basel, Switzerland. Leading experts will come together 17 – 21 April 2026, in Munich, Germany.
Session Details:
- Session Title: E0693 Can vancomycin therapeutic drug monitoring detect acute kidney injury before serum creatinine
- Date and Time: April 20 at 1400 hours
- Poster title: Can therapeutic drug monitoring improve detection of vancomycin-associated acute kidney injuries?
Who: Dr. Marc Scheetz, Professor and Director of Pharmacometrics Center of Excellence, Midwestern University. Abstract co-authored Sophie Leech and Paul Sabourenkov.
Where: The session will be promoted during the ePoster flash session in Arena 1.
Additional Resources
Connect with DoseMe on LinkedIn
Visit the DoseMe Newsroom
Contact DoseMe
About DoseMe
DoseMe is the provider of Firstline and DoseMeRx clinical decision support technologies that enable proactive, personalized care. Firstline is a mobile-first platform making treatment guidance accessible to every clinician, anywhere. DoseMeRx delivers clinically validated PK/PD models to individualize precision dosing in seconds. DoseMe’s evidence-based clinical intelligence helps reduce adverse drug events, antibiotic overuse, improved adherence to stewardship guidance, and provides clinicians a clear path to optimal care. For more information and real-world success stories, visit https://doseme-rx.com/success-stories